(Total Views: 489)
Posted On: 09/30/2020 10:29:20 AM
Post# of 155256
Peacekat,
I completely agree. It is a challenge with a new disease and shifting expectations to guess correctly when designing trials. Though only P2, CD10 was successful.
Unfortunately m/m not a clinical indication about which fda seems to care any longer.
Severe/critical and long haulers/persistent dysfunction seem to be current focus.
Hopefully Cytodyn is ahead of us and following up with CD10 and EIND patients as suggested by Rubraquercus.
I completely agree. It is a challenge with a new disease and shifting expectations to guess correctly when designing trials. Though only P2, CD10 was successful.
Unfortunately m/m not a clinical indication about which fda seems to care any longer.
Severe/critical and long haulers/persistent dysfunction seem to be current focus.
Hopefully Cytodyn is ahead of us and following up with CD10 and EIND patients as suggested by Rubraquercus.
(1)
(0)
